Sekido S, Ninomiya K, Iwasaki M
Cancer Treat Rep. 1979 Jun;63(6):961-70.
A novel nitrosourea derivative, methyl-6-[[[(2-chloroethyl)nitrosoamino]carbonyl]-amino]-6-deoxy-alpha-D-glucopyranoside (MCNU), is a water-soluble compound in which a methoxyl group is attached to the C-1 position and an N-(2-chloroethyl)-N-nitrosoureido group is attached to the C-6 position of the glucose moiety. MCNU exhibited a marked life-prolongation or growth-inhibitory effect against mouse L1210 leukemia, adenocarcinoma 755, Nakahara-Fukuoka sarcoma, Lewis lung carcinoma, and B16 melanoma. Ip, oral, or iv administration of MCNU was markedly effective against L1210 leukemia, and the therapeutic ratio by ip administration was larger than that of chlorozotocin or CCNU. The life-prolongation effect of MCNU against established Lewis lung carcinoma was similar to that of methyl-CCNU. The bone marrow toxicity of MCNU was less than that of CCNU but considerably more than that of chlorozotocin.
一种新型亚硝基脲衍生物,甲基-6-[[[(2-氯乙基)亚硝基氨基]羰基]-氨基]-6-脱氧-α-D-吡喃葡萄糖苷(MCNU),是一种水溶性化合物,其中甲氧基连接在C-1位,N-(2-氯乙基)-N-亚硝基脲基连接在葡萄糖部分的C-6位。MCNU对小鼠L1210白血病、腺癌755、中原-福冈肉瘤、Lewis肺癌和B16黑色素瘤表现出显著的延长生命或生长抑制作用。腹腔注射、口服或静脉注射MCNU对L1210白血病均有显著疗效,腹腔注射的治疗指数高于氯脲霉素或环己亚硝脲。MCNU对已建立的Lewis肺癌的延长生命作用与甲基环己亚硝脲相似。MCNU的骨髓毒性小于环己亚硝脲,但远大于氯脲霉素。